Recursion Pharmaceuticals, Inc. RXRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total current liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total current liabilities of $129.7M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total current liabilities decreased by 8.7% year-over-year, from $141.98M to $129.7M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total current liabilities has grown at a 44.9% compound annual growth rate (CAGR), from $23.1M to $147.71M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.